March 3, 2026Open Access

Targeting Colorectal Cancer Stem Cells Through Inhibition of the Fibroblast Growth Factor Receptor 4 Pathway with a Novel Antibody

Key Points

Successful identification of CSC-selective membrane antigens highlights potential therapeutic targets.
FGFR4 inhibition using the anti-FGFR4 3B6 monoclonal antibody reveals diagnostic and therapeutic promise.
The development of the 3B6 antibody specifically targets colorectal cancer stem cells effectively.
Implications for colorectal cancer therapy emphasize the need for targeting stem cell pathways in treatment strategies.

Abstract

This study successfully identified several CSC-selective membrane antigens that can become therapeutic targets in CRC. Among them, we focused on FGFR4 as a promising target and developed the anti-FGFR4 3B6 monoclonal antibody which offers potential for both diagnostic and therapeutic applications.

Bookmark

View Full Paper

Cite This Study

Filocamo et al. (Wed,) studied this question.

synapsesocial.com/papers/69a75d0cc6e9836116a26741 https://doi.org/https://doi.org/10.3390/cancers18030418

Bookmark

View Full Paper